I understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. Australia and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.Assuming Novavax wins EUAs, it should be set to make a boatload of money.
The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.It's not surprising at all to me that analysts are bullish about the vaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.
- Forums
- ASX - By Stock
- Novavax and IDT Partnership
I understand why some might be skeptical about Novavax...
Featured News
Add IDT (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $53.73M |
Open | High | Low | Value | Volume |
12.5¢ | 12.8¢ | 12.5¢ | $18.81K | 150.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 85680 | 12.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 338664 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 85680 | 0.125 |
5 | 308999 | 0.120 |
8 | 785476 | 0.115 |
8 | 438201 | 0.110 |
3 | 409533 | 0.105 |
Price($) | Vol. | No. |
---|---|---|
0.130 | 338664 | 3 |
0.135 | 60641 | 3 |
0.140 | 90000 | 3 |
0.145 | 114987 | 3 |
0.150 | 290870 | 5 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
IDT (ASX) Chart |